epiClinicalA fictional CRO

epiClinical is fictional. It is a portfolio demonstration by Adam Daniels. Its studies, sponsors, sites and enrolment figures are synthetic. The evidence behind its assumptions is real, and every number says how far it can be trusted.

EPI-301, Phase III. Recruiting

Non-small cell lung cancer, second line

NWT-4471 with docetaxel against docetaxel alone in previously treated non-small cell lung cancer. Sponsor: Northwind Therapeutics (fictional), Oncology.

Where EPI-301 stands on September 30th 2026

  • Randomised171of 400 needed
  • Sites open159of 159 planned
  • Median forecast finishAug 2027Deadline Jan 2028
  • FinishOn timeMedian forecast 5 months before the deadline.Open the plan
  • Enrolment82% of planRandomised to date against the count the plan expected by now.Open KPIs
  • Sites5 of 10 behindSites below their own expectation. The colour pools every site against what sites of their kind should recruit, so it changes only when the shortfall is more than chance.Open Sites
  • KRIs19 of 159 flaggedSites over at least one KRI threshold, each a candidate for a call, a targeted review or a visit.Open KRIs
  • QTLsAll 4 withinStudy-level quality limits, judged once enough patients are in.Open QTLs

By country

EPI-301 by country
CountrySites openRandomisedBehindWaiting too long for a first patientOver a KRI threshold
United States50 of 50391 of 1–2 of 50
United Kingdom25 of 25420 of 1–6 of 25
Spain35 of 35521 of 3–7 of 35
Poland25 of 2515––1 of 25
Turkey12 of 12131 of 2–2 of 12
India12 of 12102 of 3–1 of 12